000181626 001__ 181626
000181626 005__ 20240229145651.0
000181626 0247_ $$2doi$$a10.1007/s00066-022-01998-z
000181626 0247_ $$2pmid$$apmid:36074138
000181626 0247_ $$2ISSN$$a0179-7158
000181626 0247_ $$2ISSN$$a1439-099X
000181626 0247_ $$2altmetric$$aaltmetric:135681041
000181626 037__ $$aDKFZ-2022-02120
000181626 041__ $$aEnglish
000181626 082__ $$a610
000181626 1001_ $$0P:(DE-HGF)0$$aWolf, Jule$$b0
000181626 245__ $$aDeep inspiration breath-hold radiation therapy in left-sided breast cancer patients: a single-institution retrospective dosimetric analysis of organs at risk doses.
000181626 260__ $$aHeidelberg$$bSpringer Medizin$$c2023
000181626 3367_ $$2DRIVER$$aarticle
000181626 3367_ $$2DataCite$$aOutput Types/Journal article
000181626 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1679666961_20144
000181626 3367_ $$2BibTeX$$aARTICLE
000181626 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000181626 3367_ $$00$$2EndNote$$aJournal Article
000181626 500__ $$a2023 Apr;199(4):379-388
000181626 520__ $$aRadiotherapy can induce cardiac injury in left-sided breast cancer cases. Cardiac-sparing irradiation using the deep inspiration breath-hold (DIBH) technique can achieve substantial dose reduction to vulnerable cardiac substructures compared with free breathing (FB). This study evaluated the dosimetric differences between both techniques at a single institution.From 2017 to 2019, 130 patients with left-sided breast cancer underwent breast-conserving surgery (BCS; n = 121, 93.1%) or mastectomy (ME; n = 9, 6.9%) along with axillary lymph node staging (n = 105, 80.8%), followed by adjuvant irradiation in DIBH technique; adjuvant systemic therapy was included if applicable. 106 (81.5%) patients received conventional and 24 (18.5%) hypofractionated irradiation. Additionally, 12 patients received regional nodal irradiation. Computed tomography (CT) scans in FB and DIBH position were performed for all patients. Intrafractional 3D position monitoring of the patient surface in deep inspiration and breath gating was performed using Sentinel and Catalyst HD 3D surface scanning systems (C-RAD, Catalyst, C‑RAD AB, Uppsala, Sweden). Individual coaching and determination of breathing amplitude during the radiation planning CT was performed. Three-dimensional treatment planning was performed using standard tangential treatment portals (6 or 18 MV). The delineation of cardiac structures and both lungs was done in both the FB and the DIBH scan.All dosimetric parameters for cardiac structures were significantly reduced (p < 0.01 for all). The mean heart dose (Dmean) in the DIBH group was 1.3 Gy (range 0.5-3.6) vs. 2.2 Gy (range 0.9-8.8) in the FB group (p < 0.001). The Dmean for the left ventricle (LV) in DIBH was 1.5 Gy (range 0.6-4.5), as compared to 2.8 Gy (1.1-9.5) with FB (p < 0.001). The parameters for LV (V10 Gy, V15 Gy, V20 Gy, V23 Gy, V25 Gy, V30 Gy) were reduced by about 100% (p < 0.001). The LAD Dmean in the DIBH group was 4.1 Gy (range 1.2-33.3) and 14.3 Gy (range 2.4-37.5) in the FB group (p < 0.001). The median values for LAD such as V15 Gy, V20 Gy, V25 Gy, V30 Gy, and V40 Gy decreased by roughly 100% (p < 0.001). An increasing volume of left lung in the DIBH position resulted in dose sparing of cardiac structures.For all ascertained dosimetric parameters, a significant dose reduction could be achieved in DIBH technique.
000181626 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000181626 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000181626 650_7 $$2Other$$aBreast cancer
000181626 650_7 $$2Other$$aCardiac-sparing
000181626 650_7 $$2Other$$aDeep inspiration breath-hold radiation therapy
000181626 650_7 $$2Other$$aHeart toxicity
000181626 650_7 $$2Other$$aLeft-sided
000181626 7001_ $$0P:(DE-HGF)0$$aStoller, Sabine$$b1
000181626 7001_ $$0P:(DE-HGF)0$$aLübke, Jördis$$b2
000181626 7001_ $$0P:(DE-HGF)0$$aRothe, Thomas$$b3
000181626 7001_ $$0P:(DE-HGF)0$$aSerpa, Marco$$b4
000181626 7001_ $$0P:(DE-HGF)0$$aScholber, Jutta$$b5
000181626 7001_ $$0P:(DE-HGF)0$$aZamboglou, Constantinos$$b6
000181626 7001_ $$0P:(DE-HGF)0$$aGkika, Eleni$$b7
000181626 7001_ $$0P:(DE-HGF)0$$aBaltas, Dimos$$b8
000181626 7001_ $$aJuhasz-Böss, Ingolf$$b9
000181626 7001_ $$aVerma, Vivek$$b10
000181626 7001_ $$aKrug, David$$b11
000181626 7001_ $$0P:(DE-HGF)0$$aGrosu, Anca-Ligia$$b12
000181626 7001_ $$0P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aNicolay, Nils$$b13$$udkfz
000181626 7001_ $$00000-0003-4052-6632$$aSprave, Tanja$$b14
000181626 773__ $$0PERI:(DE-600)2003907-4$$a10.1007/s00066-022-01998-z$$n4$$p379-388$$tStrahlentherapie und Onkologie$$v199$$x0179-7158$$y2023
000181626 909CO $$ooai:inrepo02.dkfz.de:181626$$pVDB
000181626 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000181626 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000181626 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000181626 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000181626 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000181626 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000181626 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000181626 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000181626 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000181626 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000181626 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000181626 9101_ $$0I:(DE-588b)2036810-0$$60000-0003-4052-6632$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000181626 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000181626 9141_ $$y2022
000181626 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-01-26$$wger
000181626 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-26
000181626 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-26
000181626 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-26
000181626 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-28
000181626 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-28
000181626 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-28
000181626 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-28
000181626 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-28
000181626 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-28
000181626 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSTRAHLENTHER ONKOL : 2022$$d2023-08-28
000181626 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-28
000181626 9201_ $$0I:(DE-He78)FR01-20160331$$kFR01$$lDKTK FR zentral$$x0
000181626 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x1
000181626 980__ $$ajournal
000181626 980__ $$aVDB
000181626 980__ $$aI:(DE-He78)FR01-20160331
000181626 980__ $$aI:(DE-He78)E055-20160331
000181626 980__ $$aUNRESTRICTED